Trial Profile
An open-label phase 2 study to evaluate the safety and efficacy of CCX168 in subjects with IgA Nephropathy on stable RAAS blockade.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2023
Price :
$35
*
At a glance
- Drugs Avacopan (Primary)
- Indications IgA nephropathy
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors ChemoCentryx
- 02 Aug 2023 Last checked against ClinicalTrials.gov record.
- 31 Jul 2023 Primary endpoints has been amended and trial focus has now shifted to TU and Ar.
- 19 Feb 2018 This trial has been completed in Sweden, according to European Clinical Trials Database record